Evidence map›Paper›PMID 40721434›Full record

ArticleScientific reports2025

Comprehensive single-cell transcriptomic analysis reveals fibroblast subpopulations and the prognostic association of COMT in prostate cancer progression, COMT , COMT.

Weimin Shan, Bo Guan, Weiwei Ma, Runzhe Fan, Di Cui, Zongyao Hao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weimin Shan *Department of Urology, Fuyang People's Hospital of Anhui Medical University, Fuyang, China.
Bo Guan *Department of Urology, Fuyang People's Hospital of Anhui Medical University, Fuyang, China. guanbo6@163.com.
Weiwei MaDepartment of Urology, Fuyang People's Hospital of Anhui Medical University, Fuyang, China.
Runzhe FanDepartment of Urology, Fuyang People's Hospital of Anhui Medical University, Fuyang, China.
Di CuiFuyang Medical College, Fuyang Normal University, Fuyang, China.
Zongyao HaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. haozongyao@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a heterogeneous malignancy with a complex tumor microenvironment (TME) composed of various cellular components, including fibroblasts. These fibroblasts, particularly cancer-associated fibroblasts (CAFs), are crucial in shaping the TME and influencing cancer progression. Catechol-O-methyltransferase (COMT), a key enzyme involved in the metabolism of catecholamines and oxidative stress regulation, has recently been implicated in cancer biology. This study aims to explore the molecular landscape of fibroblasts in prostate cancer and evaluate the prognostic significance of COMT expression in this context. We performed an integrated single-cell RNA sequencing (scRNA-seq) analysis on prostate cancer samples from Gene Expression Omnibus (GEO) databases. Fibroblast subpopulations were identified through clustering, and functional gene signatures for each subgroup were characterized. Prognostic analysis was carried out using univariate and multivariate Cox regression to identify genes associated with patient survival, culminating in a risk score model using data from the Cancer Genome Atlas (TCGA). Additionally, immunofluorescence assays were used to validate COMT expression in tumor-derived fibroblasts. Our single-cell sequencing analysis revealed three distinct fibroblast subpopulations, each with unique gene expression profiles linked to extracellular matrix remodeling, immune modulation, and cellular stress responses. COMT was identified as a key gene in tumor-derived fibroblasts, with its expression significantly higher in tumor samples compared to normal tissues. The risk score model, based on COMT and other fibroblast-associated genes (QSOX1, TAX1BP3, CCDC66, MTCH1, ARL2BP), successfully stratified patients into high-risk and low-risk groups, with higher risk scores correlating with poorer survival outcomes. Immunostaining confirmed the overexpression of COMT in tumor-derived fibroblasts, consistent with bioinformatics analysis. This study underscores the significant role of fibroblasts, particularly CAFs, in prostate cancer progression. Our findings highlight COMT as a critical regulator of the tumor microenvironment and a promising prognostic marker. The integration of single-cell RNA-seq with clinical data offers new insights into fibroblast heterogeneity and the potential for COMT as a therapeutic target in prostate cancer. Further research is needed to validate these findings and explore the mechanistic role of COMT in prostate cancer progression and therapeutic resistance.

Indexed as

Cancer-Associated FibroblastsCatechol O-MethyltransferaseProstatic NeoplasmsTranscriptomeBiomarkers, TumorDisease ProgressionFibroblastsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMalePrognosisSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorCatechol O-MethyltransferaseCOMT protein, humanCatechol-o-methyltransferaseFibroblastPrognostic markersProstate cancerSingle-cell sequencing

Identifiers

PMID40721434
PMCPMC12304398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.